FMP
Tarsus Pharmaceuticals, Inc.
TARS
NASDAQ
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
32.76 USD
-0.95 (-2.9%)
About
ceo
Dr. Bobak R. Azamian M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.tarsusrx.com
exchange
NASDAQ
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceutical...
CIK
0001819790
ISIN
US87650L1035
CUSIP
87650L103
Address
15440 Laguna Canyon Road
Phone
949 409 9820
Country
US
Employee
244
IPO Date
Oct 16, 2020
Summary
CIK
0001819790
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
87650L103
ISIN
US87650L1035
Country
US
Price
32.76
Beta
1.05
Volume Avg.
739.75k
Market Cap
1.23B
Shares
-
52-Week
12.57-40.4
DCF
6.43
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-7.09
P/B
-
Website
https://www.tarsusrx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TARS News
It looks like there's no news available.
